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Introduction
Cancer has been one of the major diseases plaguing the 
world for millennia. Thousands of new cases are reported 
each year with high fatality rates.1 Women have a 1 in 8 
chance of getting diagnosed with breast cancer in Malaysia, 
where it is the most common cancer reported. Although 
conventional treatment such as chemotherapy is available 
to suppress the onset and progress of cancer, the severe side 
effects and the possibility of relapse and pain coupled with 
varied chances of success dampen the treatment.2
In order for a cancer treatment to be considered a viable 
option, it has to not only kill or slow down the growth of 
the tumor but it needs to stop the spread of the cancer as 
well. Metastasis is a process whereby cancer cells migrate 
to distant organs or secondary sites in the body and prolif-
erate.3 It is estimated that 90% of fatalities in cancer 
patients are brought about by metastasis rather than the pri-
mary tumor. For metastasis to take place, several crucial 
steps must occur, such as angiogenesis and invasion. 
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Abstract
Although it may sound unpleasant, camel urine has been consumed extensively for years in the Middle East as it is believed 
to be able to treat a wide range of diseases such as fever, cold, or even cancer. People usually take it by mixing small 
drops with camel milk or take it directly. The project aims to study the effects of camel urine in inhibiting the growth 
potential and metastatic ability of 4T1 cancer cell line in vitro and in vivo. Based on the MTT result, the cytotoxicity of 
camel urine against 4T1 cell was established, and it was dose-dependent. Additionally, the antimetastatic potential of camel 
urine was tested by running several assays such as scratch assay, migration and invasion assay, and mouse aortic ring assay 
with promising results in the ability of camel urine to inhibit metastatic process of the 4T1 cells. In order to fully establish 
camel urine’s potential, an in vivo study was carried out by treating mice inoculated with 4T1 cells with 2 different doses 
of camel urine. By the end of the treatment period, the tumor in both treated groups had reduced in size as compared 
to the control group. Additional assays such as the TUNEL assay, immunophenotyping, cytokine level detection assay, 
clonogenic assay, and proteome profiler demonstrated the capability of camel urine to reduce and inhibit the metastatic 
potential of 4T1 cells in vivo. To sum up, further study of anticancer properties of camel urine is justified, as evidenced 
through the in vitro and in vivo studies carried out. Better results were obtained at higher concentration of camel urine 
used in vivo. Apart from that, this project has laid out the mechanisms employed by the substance to inhibit the growth 
and the metastatic process of the 4T1 cell.
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Interference at any of the steps will lead to termination of 
the metastatic cascade.4
As unpleasant as it sounds, the consumption of camel 
urine is one of the many treatment options that has been 
available in the Arabian Peninsula for centuries. In recent 
years, its medicinal claim has been put under scrutiny and 
with promising results, whereby it is reported to exhibit 
antifungal activity and able to protect liver from damage 
induced by CCl
4
.5,6 Moreover, it is able to kill several can-
cer cell lines at an acceptable dosage.7,8 Nonetheless, its 
mechanism in inhibiting the metastatic potential of cancer 
cell has not been properly investigated and there have been 
few animal models tested so far. As such, the mechanism of 
camel urine inhibiting tumor growth and the metastatic pro-
cess of breast cancer cells was tested using several assays 
such as MTT assay, proteomic profiler assay, and real-time 
polymerase chain reaction (PCR).
Methods
Preparation of Camel Urine Sample
The urine sample was collected from Magateer female vir-
gin camel from Riyadh, Saudi Arabia, aged 8 years, during 
feeding time into stainless steel containers and kept at 
−80°C until further use. Urine (10 mL) was aliquoted into 
15-mL falcon tubes and freeze dried using FreeZone Freeze 
Dry Systems (Labconco, Kansas City, MO) at Laboratory 
of Marine Biotechnology, IBS. Stock solution was prepared 
by dissolving the powdered urine sample in phosphate-
buffered saline (PBS) and filtered through Minisart syringe 
filter (Sigma, St Louis, MO) pore size 0.2 µm and kept at 
4°C until further use.
Cell Lines and Cell Cultures
Mouse mammary tumor 4T1 cell (ATCC No. CRL-2539) 
was obtained and thawed from Animal Tissue Culture 
Laboratory, Department of Cell and Molecular Biology, 
Universiti Putra Malaysia. The cell was grown and main-
tained in RPMI-1640 media (Sigma) supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (FBS; PAA, 
Pasching, Austria), penicillin (100 IU/mL), and streptomy-
cin (100 ng/ML; PAA) in 90% humidified incubator at 
37°C with 5% CO
2
.
MTT Cytotoxic Assay
To determine the IC
50
 of camel urine, and hence its cyto-
toxic potential, it was evaluated using the 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay.9 Two-fold serial dilutions of camel urine were tested 
on the 4T1 cell line seeded at a concentration of 0.8 × 105 
cells/mL for 24 hours before treatment was added, with 
further incubation at 3 different time points, which were 24, 
48, and 72 hours. At each respective time point, 20 µL of 
MTT solution (Calbiochem, San Francisco, CA; 5 mg/mL) 
was added into each well and further incubation was done 
for another 4 hours before 170 µL of media was discarded 
from each well at the end of the incubation time. Then, 100 
µL of dimethyl sulfoxide was added into each well and 30 
minutes incubation period ensued to dissolve the blue 
formazan crystal formed at the bottom of the well. The 
plates were tapped gently before the reading was recorded 
at 570 nm in a µQuant ELISA Reader (Bio-Tek Instruments, 
Winooski, VT). Percentage of cell viability was then calcu-
lated using the following formula:
Absorbance of sample/
Absorbance of control
  100%





 ×
The concentration of camel urine that inhibited 50% of 
cell viability (IC
50
) was determined by plotting the absor-
bance value and establishing the connecting point between 
the percentage of cell viability and concentration of test 
substance.
In vitro Scratch Assay
This assay was carried out according to the protocol out-
lined by Liang et al.10 4T1 cells were seeded at concentra-
tion of 2.4 × 105 cells/mL in 6-well plates for 24 hours and 
incubated in a 90% humidified incubator at 37°C with 5% 
CO
2
. After 24 hours, a sterile yellow tip was used to scratch 
a straight line in the middle of the wells and the media was 
discarded before fresh media with 3 different concentra-
tions of camel urine—2 mg/mL, 1 mg/mL, and 0.5 mg/mL—
were introduced into the wells. Images were captured using 
Diaphot Phase Contrast-2 EL WD 0.3 fluorescence micro-
scope at 0, 20th, and 24th hour to determine the rate of 
migration (Nikon, Tokyo, Japan). The rate of migration was 
determined using the following formula:
Area of woundat
Area of woundat
Area of woundat
0
0
100
H
n H
H
−
( )
×
Migration and Invasion Assays
In this assay, the ability of camel urine to inhibit the mortal-
ity of 4T1 cells was investigated by migration and invasion 
assays using culture insert (Becton Dickinson, Franklin 
Lakes, NJ). In summary, 4T1 cells were seeded at a concen-
tration of 5 × 105 cells/mL inside cell culture insert and 
treated with 3 different concentrations determined from the 
MTT cytotoxic assay, which were 2 mg/mL, 1 mg/mL, and 
0.5 mg/mL. Three independent, biological replicates were 
carried out. One day before seeding and treatment, media 
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with FBS serum was aspirated from the culture flask of 4T1, 
and it was replaced with media without serum. The cell cul-
ture insert was placed in each well of a 6-well plate. For 
invasion assay, 100 µL of matrigel (Becton-Dickinson) was 
added and allowed to set for an hour. Then, 4T1 cells were 
seeded inside the cell culture insert and treatment was added 
immediately before the plate was incubated in a 90% humid-
ified incubator at 37°C with 5% CO
2
 for 24 hours. Then, the 
insert was removed from the well and fixed with 100% 
methanol for 2 hours before it was stained with crystal violet 
for 1 hour. Stained cells were observed under Diaphot Phase 
Contrast-2 EL WD 0.3 fluorescence microscope (Nikon). 
Migrated or invaded cells were counted in each experiment 
in 4 different pictures taken for each replicate.
Ex Vivo Mouse Aortic Ring Assay
Ex vivo mouse aortic ring assay can be utilized to study 
angiogenesis and the effectiveness of drugs or compounds 
in affecting angiogenesis.11 BALB/c mice of age of 7 weeks 
were sacrificed and the dorsal aorta was harvested, rinsed 
with ice-cold PBS a few times, and cut into approximately 
1.5-mm pieces. Then, each piece was inserted in a 96-well 
plate that had been precoated with matrigel. Another layer 
of matrigel was sandwiched on top afterwards and it was 
allowed to solidify before EGM media with camel urine at 
a concentration of 4 mg/mL was added to the wells. The 
plate was incubated in a 90% humidified incubator at 37°C 
with 5% CO
2
 for 7 days before it was observed under 
Diaphot Phase Contrast-2 EL WD 0.3 fluorescence micro-
scope (Nikon). This assay was carried out according to the 
protocol outlined by Baker et al.11
Animals
Female BALB/c mice were purchased from Animal House of 
the Faculty of Veterinary Medicine, Universiti Putra 
Malaysia, aged around 7 weeks with average body weight of 
20 to 22 g and placed in plastic cages with temperature mod-
ulated at approximately 22 ± 1°C and 12 hours of dark/light 
cycle with humidity around 60%. They were allowed to 
acclimatize for 7 days and received standard pellet diet and 
distilled water ad libitum for the whole duration of the exper-
iment. This study was approved by the Animal Care and Use 
Committee, Universiti Putra Malaysia (UPM/IACUC/AUP- 
096/2014), according to the guidelines from the committee.
In Vivo Antitumor Effect on 4T1-Challenged 
BALB/c Mice
Mice were divided into 3 groups with 5 mice in each group, 
and 2 concentrations were chosen.12 Each mouse was inoc-
ulated with 4T1 cell line at a concentration of 1 × 106 cells/
mL subcutaneously, and 1 week of incubation period was 
allowed for the tumor to grow before the treatment phase 
commenced. The arrangement for the treatment phase was 
as follows:
Control: 100 µL of distilled water
Low dose: 100 µL of 120 mg/kg extract
High dose: 100 µL of 240 mg/kg extract
All treatments were administered orally daily for 28 days 
through oral gavage. Mice were monitored twice per day 
for 28 days until they were sacrificed through cervical dis-
location. Organs and blood were collected prior to the fol-
lowing assays.
Histopathology Analysis Using Hematoxylin and 
Eosin (H&E) Stain Staining
The cell division of tumors was observed in H&E staining. 
Half of the tumors were collected and fixed in 10% neutral 
buffered formalin before they were sent to the Histopathology 
Laboratory, Faculty of Veterinary Medicine, Universiti 
Putra Malaysia, for sectioning and staining with hematoxy-
lin and eosin stain. In short, the stained tissues were 
observed under a Diaphot Phase Contrast-2 EL WD 0.3 
microscope (Nikon).
Antioxidant Activity in Tumor Sample
Antioxidant activity in tumor sample was investigated by 
measuring the activity of malondialdehyde (MDA) and 
nitric oxide (NO). Tumors were weighed and mashed in ice-
cold PBS solution before they were centrifuged at 8000 × g 
for 10 minutes in 4°C. For quantification of NO, the assay 
was carried out using Griess Reagent Kit for Nitrite 
Determination (Molecular Probes, Eugene, OR) in accor-
dance to the user guidelines provided. For quantification of 
MDA, this assay was carried out according to the protocol 
outlined by Suhail et al.13 Two hundred microliters of sam-
ple was mixed with 800 µL of PBS, 25 µL of butylated 
hydroxytoulene (BHT; 44 mg/5mL absolute ethanol solu-
tion), and 500 µL of 30% trichloroacetic acid before the mix-
ture was subjected to vortex and incubated in ice for 2 hours. 
After 2 hours, it was centrifuged at 2000 × g for 15 minutes 
at room temperature. Then, 1 mL of supernatant obtained 
was mixed with 75 µL of 0.1 M EDTA and 250 µL of 1% 
thiobarbituric acid in 1 M NaOH and boiled for 15 minutes. 
After the solution cooled down to room temperature, the 
absorbance is recorded at 600 nm and 532 nm using a spec-
trophotometer (Beckman Coulter, Carlsbad, CA).
Clonogenic Assay
The metastasis of 4T1 cells to other parts from the primary 
tumor site was investigated by clonogenic assay. Liver, 
lung, and brain were harvested under sterile condition, 
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mashed, and incubated with ice-cold PBS and collagenase 
for 30 minutes in a water bath at 37°C with shaking at every 
5-minute interval. Then, they were strained and spun down 
before they were suspended in 10 mL selection medium. 
Ten-fold serial dilution was carried out for each organ for 
each plate and they were incubated in a 90% humidified 
incubator at 37°C with 5% CO
2
 for 10 days. Then, the plates 
were fixed with 100% methanol and stained with 0.5% 
crystal violet. The degree of 4T1 metastasis was determined 
by counting the colony formed in each well.
Immunophenotyping of Spleen CD4, CD8, and 
NK 1.1 T Cells
Spleens were harvested, mashed in cold PBS, and strained 
through 80 µm wire mesh before being treated with lysis 
buffer (see the appendix). Then, they were pelleted down at 
2000 × g for 5 minutes, resuspended in ice-cold PBS again, 
and divided into 2 tubes. After that, they were stained with 
CD3/CD4/CD8 (Abcam, Cambridge, MA) and NK1.1/CD3 
(Abcam) antibodies and incubated for 2 hours on ice. After 
2 hours, they were pelleted down and 1 mL of PBS was 
added before they were analyzed using a FACS Calibur 
flow cytometer (Becton-Dickinson).
Serum Cytokine ELISA Assay
The concentration of IL-1β and IL-10 secreted by spleens 
were verified from the serum samples. Serum samples were 
collected and kept in a −20°C freezer before they were ana-
lyzed using Mouse IL-1β ELISA MAX and Mouse IL-10 
ELISA MAX (BioLegend, San Francisco, CA) in accor-
dance to the user guidelines provided.
Terminal dUTP Nick End Labeling (TUNEL) 
Assay
Unstained tumor slides were prepared by the Histopathology 
Laboratory, Faculty of Veterinary Medicine, Universiti 
Putra Malaysia. TUNEL assay was carried out using 
DeadEnd Colorimetric TUNEL system kit (Promega, 
Fitchburg, WI) according to the user guidelines provided.
Splenocyte Cytotoxicity Assay
The activity of splenocyte cytotoxicity was determined by 
incubating harvested spleen with Yac-1 cell line and assess-
ing the activity by using CytoTox 96 nonradioactive cyto-
toxicity assay kit (Promega). In brief, spleens were 
harvested, mashed, and strained through a wire mesh. Then, 
they were seeded in 96-well plate with Yac-1 cells at the 
ratio of 5:1 and 2:1 of effector–target before they were incu-
bated in a 90% humidified incubator at 37°C with 5% CO
2
 
for 24 hours. The percentage of cytotoxicity was deter-
mined by using the following formula:
Percentage of cytotoxicity %  = 
Experimental  Effector sp
( )
− ontaneous  
Target spontaneous
/
Target maximum  Tar
−
−






get spontaneous   100( ) ×
Quantitative Real-Time PCR Assay
The tumors harvested from the mice were kept in RNALater 
(Qiagen, Venlo, Netherlands) before total RNA was isolated 
using RNeasy mini kit (Qiagen) in accordance to the user 
guidelines provided. The total RNA was reverse transcribed 
into cDNA using the QuantiTect Reverse Transcription kit 
(Qiagen) in accordance to the user guidelines provided. 
After that, the cDNA was put through the RT-PCR analysis 
with iQ5 RT-PCR machine (Bio-Rad, Berkeley, CA) and 
the data obtained were analyzed using the iQ5 data analysis 
software. The primer sequences used are given in Table 1.
Mouse Angiogenesis Proteomic Profiler
The effect of camel urine on the protein level affecting the 
angiogenesis process in 4T1 tumor was investigated using 
RayBio Mouse Angiogenesis Antibody Array 1 (RayBiotech, 
Norcross, GA) in accordance to the user guidelines pro-
vided. The tumors excised from the mice were snap-frozen 
with liquid nitrogen and mashed with sterilized mortar and 
pestle. The protein was extracted from the tumor using RIPA 
buffer (NaCl, Triton X-100, C
24
H
39
NaO
4
, SDS, Tris). The 
RIPA buffer was supplemented with protease cocktail inhib-
itor (Roche, Indianapolis, IN) before further use. The con-
centration obtained was quantified using Bradford assay 
(Sigma).
Statistical Analysis
All data were represented as means ± standard deviations of 
means. The analysis was performed with one-way analysis 
of variance (ANOVA) and the group means were compared 
by Duncan test. P values <.05 were considered as statisti-
cally significant.
Results
Camel Urine Inhibited Proliferation of 4T1 Cells 
In Vitro
The MTT assay was carried out to determine the ability of 
camel urine to inhibit proliferation of mouse breast cancer 
cell line, 4T1. Two-fold serial dilutions of camel urine were 
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administered onto the 4T1 cell line for 72 hours before fur-
ther readings were recorded. Based on Figure 1, camel urine 
was able to inhibit proliferation of 4T1 cells in vitro in a 
dose-dependent manner where the half-maximal inhibitory 
concentration (IC
50
) for camel urine was 2 mg/mL after 48 
hours of treatment.
The Motility and Invasiveness of 4T1 Cells Were 
Inhibited by Camel Urine In Vitro
In order to determine the antimetastatic activity of camel 
urine, the wound-healing assay was carried out. Based on 
the result obtained from Figure 2A, it was safe to assume 
the rate of migration of 4T1 cells toward the center of the 
wound was inversely proportional to the concentration of 
camel urine administered in the assay, wherein as the con-
centration of the camel urine administered increased, the 
rate of migration of 4T1 cells toward the center of the 
wells decreased. The rate of migration was compared 
between control and treatment groups. Based on Figure 
2A, the rate of migration for IC
25
 treatment group was at 
20.08 ± 1.54% as compared to the control group, which 
was at 52.38 ± 1.38%. The IC
50
 treatment group produced 
the most significant result whereby at the concentration of 
2 mg/mL, it managed to reduce the rate of migration down 
to 9.97 ± 2.01%.
In order to further validate the results obtained from the 
wound-healing assay, the transwell in vitro migration assay 
was conducted. Based on the result obtained from Figure 
2B, it can be seen that the rate of migration through the 
transwell membrane was inversely proportional to the dose 
used. In the in vitro migration assay, the percentage of 
migrated cells in the IC
25
 treatment group was at 78.41 ± 
4.67%, while in the IC
50
 treatment group the percentage 
was reduced to half at 51.11 ± 6.30%. Similar patterns were 
observed in the in vitro invasion assay based on Figure 2C, 
where the rate of invasion was dose-dependent, wherein 
higher dose led to lower rate of invasion. For the IC
25
 treat-
ment group, the rate of invasion was at 70.41 ± 7.14%, and 
the rate decreased significantly as compared to the control 
group for the IC
50
 treatment group at 52.72 ± 6.74%.
Camel Urine Showed Anti-Angiogenic Potential
Apart from inhibiting the migration and invasion capabili-
ties of cancer cells, it is important to be able to inhibit the 
angiogenesis step, which plays an important role in the 
metastatic cascade. In order to establish the anti-angiogenic 
potential of the camel urine, the ex vivo mouse aortic ring 
assay was carried out. Based on Figure 3, camel urine man-
aged to reduce the formation of vessels sprouted out from 
the fragmented aorta from 26 ± 3.79 in the control group to 
zero in the IC
50
 treatment group.
Table 1. The Primer Sequence Used in Real Time-Polymerase Chain Reaction.
Accession Number Gene Sequence
NM_007393.3 ACTB F: 5-TTCCAGCCTTCCTTCTTG-3
 R: 5-GGAGCCAGAGCAGTAATC-3
NM_013556.2 HPRT F: 5-CGTGATTAGCGATGATGAAC-3
 R: 5-AATGTAATCCAGCAGGTCAG-3
NM_008084.3 GAPDH F: 5-GAAGGTGGTGAAGCAGGCATC-3
 R: 5-GAAGGTGGAAGAGTGGGAGTT-3
NM_008689.2 NF-κβ F: 5-CATTCTGACCTTGCCTATCT-3
 R: 5-CTGCTGTTCTGTCCATTCT-3
NM_010849.4 C-MYC F: 5-TGATGTGGTGTCTGTGGAGAA-3
 R: 5-CGTAGTTGTGCTGGTGAGTG-3
NM_010927.3 iNOS F: 5-GCACCGAGATTGGAGTTC-3
 R: 5-GAGCACAGCCACATTGAT-3
NM_010493.2 ICAM1 F: 5-TGCTCAGGTATCCATCCATCC-3
 R: 5-ACGGTGCCACAGTTCTCAA-3
Figure 1. MTT analysis of 4T1 cells after treatment with 7 
concentrations (30 mg/mL to 0.4 mg/mL) of camel urine. The 
data are expressed as mean ± standard error of mean and the 
experiments were done in triplicates, P < .05.
Romli et al 545
Camel Urine Inhibited 4T1 Cancer Cell Growth 
In Vivo
In order to determine the effect of camel urine on 4T1 cell 
growth in mice, the final weight of the tumor was deter-
mined. When comparing between the control and treated 
groups, significant differences were observed between the 
groups where the control group tumor clocked in weight at 
1.66 ± 0.12 g and lower tumor weight was observed in both 
low-dose (1.26 ± 0.07 g) and high-dose (1.16 ± 0.27 g) 
groups while only a marginal difference was observed 
between low-dose and high-dose groups as illustrated in 
Figure 4A and B. Further analysis was carried out using 
TUNEL assay to determine the extent of cell apoptosis in 
the treated groups. Based on Figure 4C, higher number of 
apoptotic cells (black circle) were observed in low-dose and 
high-dose groups as compared to the control group. 
Moreover, the effect of camel urine in inhibiting 4T1 cell 
growth was further validated in H&E staining whereby 
lower number of mitotic cells were present in low dose as 
compared to the control group as seen in Figure 4D. A simi-
lar pattern was observed in high-dose group as well where 
the number of mitotic cells decreased.
Camel Urine Regulated Several Cytokines and 
Immune-Related Markers In Vivo
To further understand the mechanism of camel urine in 
affecting cancer, the blood serum of the mice was collected 
and analyzed to measure the level of 2 cytokines, IL-1β and 
Figure 2. Percentage of wound closure, migrated cells, and invaded cells of 4T1 cells. (A) Percentage of wound closure of 4T1 cells 
after a scratch was introduced in the middle section. Images were captured at 0 hour and 21 hours. Measurement was taken between 
the dotted lines where the blue arrow was placed to represent the size of the wound. (B) Percentage of migrated 4T1 cells in the 
in vitro transwell migration assay. The presence of blue/purple dots against white background was counted at 3 different sections 
of the photograph. (C) Percentage of invaded 4T1 cells in the in vitro transwell invasion assay. The presence of blue/purple dots 
against white background was counted at 3 different sections of the photograph. Two different doses (IC
25
 and IC
50
) were used for all 
assays. The assay was done in triplicate and the data are expressed as mean ± standard error of mean. Significance is set at *P < .05. 
Magnification 10×.
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IL-10. According to Figure 5, treatment of the mice with 
camel urine inhibited the activation of IL-1β in the treat-
ment group as compared to the control group, although not 
significantly. The control group had a reading of 666.51 ± 
11.11 pg/mL of IL1-β, while the low-dose and high-dose 
groups showed lower readings at 549.84 ± 50 pg/mL and 
585.80 ± 14 pg/mL of IL-1β, respectively. A similar pattern 
was observed in regard with the concentration of IL-10 in 
the blood serum where lower readings were detected in the 
treated group. A reading of 324.61 ± 9.52 pg/mL of IL-10 
was clocked in for the control group while the treated 
groups showed readings at 297.9 ± 1.87 pg/mL of IL-10 for 
the low-dose group and 298.42 ± 7.14 pg/mL of IL-10 for 
the high-dose group.
Immunophenotyping analysis was carried out to deter-
mine the presence of certain immune cell subsets in the 
mice splenocytes. Three immune cell subsets were detected 
in this analysis: CD3/CD4 subset, CD3/CD8 subset, and 
CD3/NK1.1 subset. In the CD3/CD4 subset, increases 
from 4.59 ± 0.004% in the control group to 7.12 ± 0.16% in 
the low-dose group and 8.07 ± 0.73% in the high-dose 
group were observed as depicted by Figure 6. There was 
also a substantial increase of CD3/CD8 subset in the treated 
group wherein the reading doubled from 2.44 ± 0.12% in 
the control group to 4.58 ± 0.10% and 4.30 ± 0.29% for the 
low-dose and high-dose groups, respectively. The third and 
final analysis on the markers of NK1.1 and CD3 showed a 
promising result as well where there were increases in both 
populations of CD3−/NK1.1+ and CD3+/NK1.1+ in the 
treated groups. In the quadrant of CD3−/NK1.1+, the read-
ing was at 0.21 ± 0.04% for the control group while the 
low-dose group had a significant reading of 0.37 ± 0.07% 
and the high-dose group at 0.33 ± 0.04%. For CD3+/
Nk1.1+, the percentage of the subset population doubled 
for low-dose and high-dose groups from 0.94 ± 0.04% in 
the control group to 1.93 ± 0.07% in the low-dose group 
and 1.85 ± 0.08% in the high-dose group.
Apart from immunophenotyping of the splenocyte to 
determine the subset, the activity of the natural killer cells 
can be established by incubating the harvested splenocytes 
with Yac-1 cells. As depicted in Figure 7, there was an 
increase in the cytotoxicity of the treated splenocytes in both 
low-dose and high-dose groups as compared to the control 
group wherein the higher cytotoxicity activity was recorded 
for 10:1 ratio group than the 5:1 ratio group. In the 5:1 ratio 
group, the cytotoxicity of the harvested splenocytes from the 
low-dose group was 42.94 ± 0.09% as compared to the con-
trol group at 36.37 ± 0.33%, while for the 10:1 ratio group, it 
is at 48.32 ± 1.55% as compared to 42.38 ± 1.55%, respec-
tively. In the high-dose group, similar patterns were detected 
between the control and high-dose groups. For the 5:1 ratio 
group, the percentage of cytotoxicity in the high-dose group 
was 47.09 ± 1.04% as compared to 36.37 ± 0.33% for the 
control group. Higher percentage of cytotoxicity was 
recorded as well in the 10:1 ratio group at 50.19 ± 1.05% for 
the high-dose group and 42.38 ± 1.55% for the control group.
Camel Urine Suppressed Inflammation Markers 
In Vivo
Several markers play important roles in regulating inflamma-
tion onset and progress in cancer patients. NO level was mea-
sured by incubating the supernatant obtained from the 
mashed tumor with Griess reagent (Molecular Probes). Based 
on Figure 8A, there was a significant decrease in the level of 
NO from 0.0015 ± 0.000038 µM NO/mg protein in the con-
trol group to 0.0009 ± 0.000021 µM NO/mg protein and 
0.00010 ± 0.000027 µM NO/mg protein in the low-dose and 
high-dose groups, respectively. A similar reduction pattern 
was observed in MDA level when comparing the control 
group with the low-dose and high-dose groups. Further evi-
dence of the capability of camel urine to suppress important 
inflammation markers was elucidated in the level of mRNA 
expression of several genes. As depicted in Figure 8B, sig-
nificant decrease of the mRNA level of iNOS, ICAM, and 
NK-κβ was observed in both low-dose and high-dose groups.
Camel Urine Exhibited Antimetastatic Potential 
In Vivo
Clonogenic assay was carried out in order to determine the 
ability of camel urine to disrupt the metastatic potential of 
Figure 3. The bar chart analysis and representative image of 
the ex vivo mouse aortic ring assay. Five different sections of the 
images were chosen for counting. The vessels protruding from 
the fragmented aorta were counted. The data are expressed as 
mean ± standard error of mean and the experiments were done 
in triplicate. Significance is set at *P < .05. Magnification 10×.
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the 4T1 cancer cell. Based on Figure 9A, there was signifi-
cant reduction in the number of colonies formed in the lung 
of the treated mice as compared to the control mice. About 
26 ± 2.31 colonies were formed in the lung of the low-dose 
treated mice while mice in the high-dose group produced a 
better result with only 12 ± 1.53 colonies formed as 
compared to 60.33 ± 9.82 colonies formed in the lung of the 
control mice. Apart from the clonogenic assay, the presence 
of abnormal or metastasized cell was also confirmed by the 
bone marrow smearing assay as depicted in Figure 9B, 
where there were abnormal cells present in the control 
group (black arrow) but not in the low-dose and high-dose 
Figure 4. Tumor weight, TUNEL analysis, and H&E staining of harvested tumor from the control, high-dose (240 mg/kg), and 
low-dose (120 mg/kg) treated mice. (A) Images of the tumor harvested from the control and treatment groups; scale in cm. (B) 
Measurement of tumor weight harvested from the mice after 28 days from commencement of treatment. (C) TUNEL analysis of 
harvested tumor from untreated and treated mice. Black circles depict cells with fragmented DNA based on presence of dark dots 
against brown background. Magnification: 20×. (D) Hematoxylin and eosin staining (H&E) of harvested tumors from untreated and 
treated mice. Black circles depict mitotic cell based on presence of dark purple spots. Magnification: 20×. The data are expressed as 
mean ± standard error of the mean for triplicates. Significance is set at *P < .05; n = 5 mice per group.
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groups. To further validate the result, the levels of several 
angiogenesis-related proteins were measured using pro-
teome profiler analysis, and based on Figure 10, their levels 
decreased in the low-dose and high-dose groups. The pro-
teins measured were GM-CSF, G-CSF, MCP-1, Leptin, and 
IL-13.
Discussion
In order for a substance to work effectively to treat cancer, 
it has to disrupt several mechanisms and pathways employed 
by the cancer cell to thrive. Two main targets that can be 
disrupted are the active proliferation and the metastatic 
mechanism of the cancer cell. Two different models are uti-
lized to evaluate the capability of camel urine to inhibit can-
cer cell proliferation and disrupt their metastatic process, 
which are the in vitro model and the in vivo murine model. 
In the in vitro study employed, camel urine showed cyto-
toxic potential against the 4T1 cells in a dose-dependent 
manner. When the result is transferred to the in vivo murine 
model for further evaluation, a similar pattern is observed 
whereby it reduced the size of the tumor in both treated 
groups significantly through apoptosis. As portrayed by the 
TUNEL assay, higher frequency of DNA fragmentation 
took place in the low-dose and high-dose groups as com-
pared to the control group, which is beneficial, as DNA 
fragmentation is one of the steps that will lead to apoptosis 
in cancer cells, hence serving as an indicator of the extent of 
the apoptotic event.14 Further evidence in favor of camel 
urine as an anticancer agent was the decline in the number 
of actively dividing cells or mitotic cells in both low-dose 
and high-dose groups as portrayed by the tumor section 
stained by hematoxylin and eosin. One of the main proper-
ties of the cancer cell is its ability to divide rapidly, as well 
as being able to sustain itself indefinitely through division.15 
Hence, it is vital for an anticancer agent to curtail and halt 
the mitotic cycle apart from inducing it into the apoptotic 
state, or else the cancer cell will overwhelm the anticancer 
agent with sheer numbers after a few cycles.
The immune system plays an important role in cancer 
progression; hence, it has been studied extensively for 
decades. It serves as a barrier against pathogens from bac-
terial or viral infections, which may cause cancer, and 
serves to inhibit and kill emerging cancer cells.16 Two dif-
ferent subsets of T cell population were investigated in this 
research, CD3+/CD4+ T helper cells and CD3+/CD8+ 
cytolytic T cells. The presence of T helper cells and cyto-
lytic T cells in both low-dose and high-dose groups is sig-
nificantly higher than in the control group. It was reported 
that cancer patients with high numbers of cytolytic T cells 
and T helper cells have better prognosis and survival rate.17 
The T helper cell is an important mediator, especially the 
Th1 cell, in activating cytolytic T cells, by secreting sev-
eral cytokines, such as IFN-γ.18 Apart from that, Th17 
helps combat tumor progression by suppressing inflamma-
tion through inhibition of inflammation-related cyto-
kines.19 Once activated, cytolytic T cells, commonly 
referred to as NK-T cells due to the presence of markers 
and activities similar to natural killer cells, will take part in 
immunosurveillance by tracking down and killing the can-
cer cells through direct lysis of the cells or by secreting 
cytotoxic cytokines.20,21 Another vital component of the 
immune system in curtailing the progression of cancer is 
the NK cell. Based on the flow cytometer analysis, a higher 
percentage of CD3−/NK1.1+ NK cell is reported in both 
treated groups at a significant amount. Besides that, the NK 
cell population in the splenocyte was also assessed by its 
activity against Yac-1 cells. The Yac-1 cell is a murine 
T-lymphoma cell that is annihilated by the natural killer 
cells in the splenocyte, which means a high specific cyto-
toxicity correlates to high number of NK cells in the sple-
nocyte as observed in the treated groups. The role of NK 
cells during viral infections such as cytomegalovirus and 
cancer progression is well established, whereby a higher 
survival rate is reported in cancer patients with extensive 
NK cell infiltration into the tumor.22,23 Nonetheless, tumor 
Figure 5. Analysis on the detection of the cytokine level (IL-1β 
and IL-10) in the serum of the control, low-dose (120 mg/kg), 
and high-dose (240 mg/kg) treated mice using enzyme-linked 
immunosorbent assay. The data are expressed as mean ± 
standard error of the mean. Significance is set at *P < .05; n = 5 
mice per group.
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cells have developed certain mechanisms to induce the 
microenvironment to become immunosuppressive and halt 
the antitumor effect of the immune cells. One of the meth-
ods employed is the secretion of IL-10.24,25 IL-10 is able to 
suppress the activation of T cells by inhibiting production 
of IL-12 and downregulating antigen presentation.26 Hence, 
it is important for an anticancer compound to disrupt the 
production of IL-10 by the tumor cells as reported in this 
research, whereby both treatment groups managed to 
reduce the concentration of IL-10.
Inflammation occurs either due to infection or is orches-
trated by the tumor, influencing various stages of tumor 
growth from initiation down to the metastatic process.27 As 
such, inflammation-related pathways have been targeted as 
a potential treatment option in order to treat cancer.28 
Several inflammatory-related genes were investigated in 
this study, noting the effect that camel urine imposed on 
their expression. The NF-κβ pathway is one of the few 
pathways utilized by the cancer cell to induce inflamma-
tion through the recruitment of immune cells.29 As observed 
Figure 6. Flow cytometry analysis of CD4, CD8, and NK1.1 on the splenocytes of the control, low-dose (120 mg/kg), and high-dose 
(240 mg/kg) groups on day 28 after 4T1 cell cancer induction. The data are expressed as means ± standard error of the mean for 
triplicates. Significance is set at *P < 05; n = 5 mice per group.
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in the results reported, camel urine is able to reduce NF-κβ 
mRNA expression in the tumor at both doses, although 
high-treatment produced better results. Apart from that, the 
treatment of the mice also downregulated iNOS mRNA 
expression, which is an important downstream cellular sig-
naling molecule in the NF-κβ pathway.30 iNOS is respon-
sible for the production of NO in the inflammatory process 
to fight infectious agents, but its role in inflammation-
related disease has been counterintuitive.31 The level of 
NO and MDA, a lipid peroxidative marker, decreased in 
both treatment groups concurrently with the expression of 
iNOS. The role of NO in accelerating forward tumor pro-
gression by enhancing the angiogenic and metastatic 
potentials of the tumor cell is well established, and current 
findings have reported elevated levels of MDA in breast 
cancer patients.32-34 Apart from iNOS, ICAM is also a 
downstream cellular molecule that can be activated through 
the NF-κβ pathway as well whereby its activation is associ-
ated with metastatic and malignant potential of several 
cancers including breast cancer.35-37
The metastatic cascade of cancer cells involves several 
important steps including migration, invasion, and angio-
genesis. The wound healing assay is considered a prelimi-
nary screen to establish the antimetastatic potential of any 
compound, as it is inexpensive and easy to assemble.38 
Based on the results obtained, the rate of cell migration 
toward the center of the well is lower when the IC
50
 concen-
tration is used. This indicates the potential of camel urine to 
inhibit cancer cell migration is better at the higher concen-
tration used. Migration or invasion of cancer cells is driven 
by the chemokine present in the microenvironment and the 
target organ; therefore, it is imperative for an anticancer 
compound to inhibit chemotaxis-based migration.39,40 A 
similar pattern to that observed in the wound healing assay 
was repeated in the migration and invasion assays, where 
higher concentrations of camel urine exhibited better activ-
ity at inhibiting cancer cell migration through the transwell 
membrane. Moreover, reduction of IL-1β level has been 
associated with reduced breast cancer cell migration and 
invasion and better overall prognosis.41,42
Angiogenesis, the formation of new blood vessels, is 
critical for a growing tumor because without sufficient oxy-
gen and nutrient supply, the growth will be hindered and the 
cancer cells at the center of the tumor will undergo necro-
sis.43 As shown in the mouse aortic ring assay, camel urine 
halted the formation of new microvessels significantly as 
compared to the control group. To further verify the potency 
of camel urine as an anti-angiogenic compound, several 
angiogenesis-related proteins were investigated as well. 
Growth factors affect the growth and metastasis of cancer 
cells; hence, several growth factors were investigated includ-
ing G-CSF and GM-CSF. G-CSF and GM-CSF are hemato-
poietic growth factors that induce the differentiation and 
activation of macrophages and granulocytes.44 When 
GM-CSF and G-CSF are administered together, they stimu-
late the pro-angiogenic cells in patients with acute myocar-
dial infarction, which is unfavorable in cancer patients.45 
Hence, they are highly expressed in several tumors includ-
ing invasive breast cancer.46,47 IL-13Rα2 is overexpressed in 
several human tumors such as derivatives of MDA-MB-231, 
in which it acts as a high affinity receptor for IL-13.48,49 
Binding of IL-13 to the receptor stimulates the formation of 
tube-like structures and neovascularization in rat cornea as 
well as activation of VCAM-1, which mediates angiogenesis 
Figure 7. Analysis of the cytotoxicity activity of splenocyte 
from the control, low-dose (120 mg/kg), and high-dose (240 mg/
kg) treated mice against lymphoma Yac-1 at the ratio of 5:1 or 
10:1 of splenocyte to Yac-1. The data are expressed as the mean 
± standard error of the mean. Significance is set at P < .05; n = 5 
mice per group.
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and leukocyte adherence to the endothelium.50,51 Apart from 
that, IL-13 will also drive cancer metastasis and invasion 
through phosphorylation of the ERK1/2 pathway and activa-
tion of AP-1 transcription factor.52 Therefore, reduction of 
IL-13 cytokine concentration in the tumor section of both 
treated groups is a favorable effect for camel urine. There 
has been growing interest in developing cancer therapy spe-
cifically targeting IL-13 and IL-13Rα2 to treat ovarian 
cancer.53
Obesity has been linked to increased incidence of breast 
cancer, and leptin, an adipoctyokine, is linked to obesity in 
postmenopausal women where a high concentration of 
leptin is detected as body fat mass increases.54 The epithe-
lial-mesenchymal transition is the first step in the metastatic 
cascade, and leptin is responsible for inducing the transition 
through the translocation and accumulation of nuclear 
β-catenin by phosphorylating GSK3β.55 Leptin also upregu-
lates the expression of IL-1β, which in return leads to the 
upregulation of VEGF, a key player in angiogenesis.56 
Interestingly, leptin was reduced in the high-dose and low-
dose treatment groups. Another feature of nuclear β-catenin 
is to activate MCP-1. MCP-1 is a CC-chemokine that 
recruits inflammatory monocytes and tumor associated 
macrophages (TAMs) to promote breast cancer metasta-
sis.57,58 According to the “seed and soil” hypothesis, each 
cancer type has a specific environment that will cater for its 
growth and determine the likelihood for the cell to migrate 
to certain organs.59 For breast cancer cells, they have spe-
cific preference to migrate to lung and bone.60 Clonogenic 
assay, which detects the presence of migrated cell to organs 
by the growth of colonies, showed reduced colony forma-
tion in treated groups. A similar pattern was observed in 
bone marrow smearing assay as well, where no abnormal 
cell was observed. This indicates the potential of camel 
urine in inhibiting the metastatic potential of the 4T1 cancer 
cell as verified with the proteomic assay.
Figure 8. Analysis of the level of lipid peroxidation and relative level of mRNA in the tumor excised from the control, low-dose 
(120 mg/kg), and high-dose (240 mg/kg) treated mice. (A) The analysis on the level of nitric oxide (NO) and malondialdehyde (MDA) 
lipid peroxidation. (B) Analysis of the relative level of the messenger RNA (mRNA) of nuclear factor (NF)-κβ, inducible nitric oxide 
synthase (iNOS), and intercellular adhesion molecule 1 (ICAM1). The data are expressed as mean ± standard error of the mean. 
Significance is set at P < .05; n = 5 mice per group.
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Figure 9. (A) Analysis of the presence of colonies in the lung excised from the control, low-dose (120 mg/kg), and high-dose (240 mg/
kg) treated mice, including representative images. (B) Analysis of the presence of abnormal cells in the bone marrow excised from the 
control, low-dose (120 mg/kg), and high-dose (240 mg/kg) treated mice. Black arrow depicts the abnormal cells in the bone marrow cell 
population. The data are expressed as mean ± standard error of the mean. Significance is set at P < .05; n = 5 mice per group.
Figure 10. Analysis of the proteome profiler of the tumors excised from the control, low-dose (120 mg/kg), and high-dose (240 mg/
kg) treated mice. The data are expressed as mean ± standard error of the mean. Significance is set at P < .05; n = 5 mice per group.
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Conclusion
The capability of camel urine in inhibiting the growth and 
metastatic potential of 4T1 cells was investigated in this 
study, and Figure 11 summarizes the effects of camel 
urine on 4T1 breast cancer cells. Based on the results pre-
sented, it is safe to make assumptions that it is capable of 
inducing cell death of 4T1 cells through DNA fragmenta-
tion and regulation of inflammation-related genes. Apart 
from that, camel urine was also able to disrupt the meta-
static mechanism of 4T1 cells through the downregula-
tion of several angiogenesis-related proteins. Hence, it 
has a potential to be further developed as an anticancer 
agent for cancer treatment.
Appendix
Preparation of Reagents
Lysis buffer 10× (per 100 mL)
100 mL distilled water
8.26 g NH
4
Cl
1.19 g NaHCO
3
200 µL 0.5 M EDTA
Adjust the pH with 1 N NaOH or 1 N HCL to 7.4
Filter with Millipore vacuum 0.22 µm filter top and store 
at 4°C
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